Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination

Ramez R. Fares, Lawrence S. Lansing, Christine A. Gallati, Shaker A. Mousa

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The focus of this review is to discuss the hypothesis that justifies the use of dual antiplatelet therapy of aspirin and clopidogrel versus monotherapy with aspirin in arterial vascular disease. By analyzing the CLARITY-TIMI and COMMIT trials, the authors discuss the appropriate use of aspirin plus clopidogrel for patients suffering acute myocardial infarction. In contrast, in the CHARISMA trial, the combination was not justified in stable high-risk patients with documented coronary disease, cerebrovascular disease or symptomatic peripheral artery disease. In two additional cardiovascular studies, the CURE and the PCI-CURE trials, the benefit of the drug combination was evident in those patients who underwent percutaneous coronary intervention and coronary artery bypass grafting. Finally, two focused cerebrovascular studies, the CARESS and the MATCH trials, were analyzed. The CARESS trial demonstrated the clinical benefit of this combination in an acute clinical setting. However, the combination proved to be ineffective in the longer-term MATCH trial. It appears from these large clinical trials that the risk-benefit of dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients but not in asymptomatic patients. The exact dose regimen and duration of combination therapy await definition and require careful assessment to optimize the anticoagulant benefit, while minimizing the hemorrhagic risk.

Original languageEnglish (US)
Pages (from-to)377-386
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number3
DOIs
StatePublished - Feb 1 2008

Fingerprint

clopidogrel
Vascular Diseases
Aspirin
Clinical Trials
Therapeutics
Cerebrovascular Disorders
Peripheral Arterial Disease
Drug Combinations
Percutaneous Coronary Intervention
Coronary Artery Bypass
Anticoagulants
Coronary Disease
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Fares, Ramez R. ; Lansing, Lawrence S. ; Gallati, Christine A. ; Mousa, Shaker A. / Antiplatelet therapy with clopidogrel and aspirin in vascular diseases : Clinical evidence for and against the combination. In: Expert Opinion on Pharmacotherapy. 2008 ; Vol. 9, No. 3. pp. 377-386.
@article{e0af81e117944a908864647dfd4d65da,
title = "Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination",
abstract = "The focus of this review is to discuss the hypothesis that justifies the use of dual antiplatelet therapy of aspirin and clopidogrel versus monotherapy with aspirin in arterial vascular disease. By analyzing the CLARITY-TIMI and COMMIT trials, the authors discuss the appropriate use of aspirin plus clopidogrel for patients suffering acute myocardial infarction. In contrast, in the CHARISMA trial, the combination was not justified in stable high-risk patients with documented coronary disease, cerebrovascular disease or symptomatic peripheral artery disease. In two additional cardiovascular studies, the CURE and the PCI-CURE trials, the benefit of the drug combination was evident in those patients who underwent percutaneous coronary intervention and coronary artery bypass grafting. Finally, two focused cerebrovascular studies, the CARESS and the MATCH trials, were analyzed. The CARESS trial demonstrated the clinical benefit of this combination in an acute clinical setting. However, the combination proved to be ineffective in the longer-term MATCH trial. It appears from these large clinical trials that the risk-benefit of dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients but not in asymptomatic patients. The exact dose regimen and duration of combination therapy await definition and require careful assessment to optimize the anticoagulant benefit, while minimizing the hemorrhagic risk.",
author = "Fares, {Ramez R.} and Lansing, {Lawrence S.} and Gallati, {Christine A.} and Mousa, {Shaker A.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1517/14656566.9.3.377",
language = "English (US)",
volume = "9",
pages = "377--386",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

Antiplatelet therapy with clopidogrel and aspirin in vascular diseases : Clinical evidence for and against the combination. / Fares, Ramez R.; Lansing, Lawrence S.; Gallati, Christine A.; Mousa, Shaker A.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 3, 01.02.2008, p. 377-386.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antiplatelet therapy with clopidogrel and aspirin in vascular diseases

T2 - Clinical evidence for and against the combination

AU - Fares, Ramez R.

AU - Lansing, Lawrence S.

AU - Gallati, Christine A.

AU - Mousa, Shaker A.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - The focus of this review is to discuss the hypothesis that justifies the use of dual antiplatelet therapy of aspirin and clopidogrel versus monotherapy with aspirin in arterial vascular disease. By analyzing the CLARITY-TIMI and COMMIT trials, the authors discuss the appropriate use of aspirin plus clopidogrel for patients suffering acute myocardial infarction. In contrast, in the CHARISMA trial, the combination was not justified in stable high-risk patients with documented coronary disease, cerebrovascular disease or symptomatic peripheral artery disease. In two additional cardiovascular studies, the CURE and the PCI-CURE trials, the benefit of the drug combination was evident in those patients who underwent percutaneous coronary intervention and coronary artery bypass grafting. Finally, two focused cerebrovascular studies, the CARESS and the MATCH trials, were analyzed. The CARESS trial demonstrated the clinical benefit of this combination in an acute clinical setting. However, the combination proved to be ineffective in the longer-term MATCH trial. It appears from these large clinical trials that the risk-benefit of dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients but not in asymptomatic patients. The exact dose regimen and duration of combination therapy await definition and require careful assessment to optimize the anticoagulant benefit, while minimizing the hemorrhagic risk.

AB - The focus of this review is to discuss the hypothesis that justifies the use of dual antiplatelet therapy of aspirin and clopidogrel versus monotherapy with aspirin in arterial vascular disease. By analyzing the CLARITY-TIMI and COMMIT trials, the authors discuss the appropriate use of aspirin plus clopidogrel for patients suffering acute myocardial infarction. In contrast, in the CHARISMA trial, the combination was not justified in stable high-risk patients with documented coronary disease, cerebrovascular disease or symptomatic peripheral artery disease. In two additional cardiovascular studies, the CURE and the PCI-CURE trials, the benefit of the drug combination was evident in those patients who underwent percutaneous coronary intervention and coronary artery bypass grafting. Finally, two focused cerebrovascular studies, the CARESS and the MATCH trials, were analyzed. The CARESS trial demonstrated the clinical benefit of this combination in an acute clinical setting. However, the combination proved to be ineffective in the longer-term MATCH trial. It appears from these large clinical trials that the risk-benefit of dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients but not in asymptomatic patients. The exact dose regimen and duration of combination therapy await definition and require careful assessment to optimize the anticoagulant benefit, while minimizing the hemorrhagic risk.

UR - http://www.scopus.com/inward/record.url?scp=39049114716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049114716&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.3.377

DO - 10.1517/14656566.9.3.377

M3 - Review article

C2 - 18220489

AN - SCOPUS:39049114716

VL - 9

SP - 377

EP - 386

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -